The overlap between reducing the risk of dementia and reducing the risk of cognitive decline is virtually identical, with pharmaceutical agents used for dementia when biomarkers like amyloid accumulation are present.

“so the um the overlap between reducing the risk of a disease known as dementia is virtually identical to the steps you take to reduce the risk of cognitive decline are there differences sure there are if you're talking about patients who were in whom we're trying to reduce the risk of dementia and for example we see serum mark of low amounts of amalo accumulation we may actually turn to pharmaceutical agents that reduce the amount of amalo there so that's something that wouldn't be in the Playbook”